SCI Abstract

search
+
A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia
A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia
A personalized prognostic model that takes into account the unique molecular features of primary myelodysplastic neoplasm ...
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Trial registration: ClinicalTrials.gov number: NCT01777152
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
Bispecific antibodies (BsAbs) have shown promise in the management of relapsed/refractory multiple myeloma (MM). Despite i...
Co-occurrence of clonally related follicular lymphoma and histiocytic sarcoma
Co-occurrence of clonally related follicular lymphoma and histiocytic sarcoma
Kommalapati A, Tella SH, Go RS, Goyal G. Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. ...
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera
Chronic systemic inflammation is a key driver of polycythemia vera (PV) progression, but the immunomodulatory effects of c...
Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
Uniform assessment of response to treatment is crucial to managing multiple myeloma (MM) and developing new therapies. Mea...
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts
Follicular lymphoma (FL) 3B is considered an aggressive lymphoma, however recent studies have challenged this paradigm. Ad...
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
Talquetamab is the first FDA approved drug targeting G-protein-coupled recep...
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Competing interests F.M. reports honoraria from Therakos/Mallinckrodt, Jan...
The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
Light-chain (LC) monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and rel...
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
To compare the efficacy and safety of gecacitinib (also known as jaktinib) with hydroxyurea (HU) in treating myelofibrosis...
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Historically, CLL prognostication relied on disease burden, reflected in clinical stage. Later, chromosome abnormalities a...
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is a kind of aggressive T-cell lymphoma with significant enrichment of non-malig...
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older
Mantle cell lymphoma (MCL) is a currently incurable lymphoma subtype, with m...
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosoma...
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/ref...
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations ...
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, et al. Core-binding factor acute myeloid leukemia: long-term...
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Competing interests MH reports research funding from Daiichi Sankyo, Coset...
Current status and research directions in acute myeloid leukemia
Current status and research directions in acute myeloid leukemia
The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeu...
Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
Multiple myeloma (MM) is characterized by complex, heterogeneous genetic abnormalities that significa...
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma
Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearr...
Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
Follicular lymphoma (FL) is a lymphoproliferative neoplasia typically considered incurable. It is mos...
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia
Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) whose clinical course is often ...
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Survey of interpretation practices of unbalanced MYC break-apart resultsFifty-four responses were obtained to the survey q...
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Competing interests EM and VG have no conflicts of interest to disclose. S...
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Myelodysplastic neoplasms (MDS) are hematopoietic stem cell (HSC) disorders arising in the bone marro...
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Nucleophosmin 1 (NPM1) is one of the most frequently mutated genes (~30% of cases) in acute myeloid l...
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with lower socioeconomic status (...
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of non-Hodgkin lymphoma primari...
Load More
format_indent_increase